Mostrar el registro sencillo del ítem

dc.contributor.authorCaravaca Perez, P.
dc.contributor.authorGonzález Juanatey, José Ramón 
dc.contributor.authorNuche, J.
dc.contributor.authorMatute-Blanco, L.
dc.contributor.authorSerrano, I.
dc.contributor.authorMartínez Selles, M.
dc.contributor.authorVázquez García, R.
dc.contributor.authorMartínez Dolz, L.
dc.contributor.authorGómez-Bueno, M.
dc.contributor.authorPascual Figal, D.
dc.contributor.authorCrespo Leiro, Marisa 
dc.contributor.authorGarcía-Osuna, A.
dc.contributor.authorOrdoñez-Llanos, J.
dc.contributor.authorCinca Cuscullola, J.
dc.contributor.authorGuerra, J.M.
dc.contributor.authorDelgado, J.F.
dc.date.accessioned2025-08-26T10:54:47Z
dc.date.available2025-08-26T10:54:47Z
dc.date.issued2022
dc.identifier.citationCaravaca Perez P, González-Juanatey JR, Nuche J, Matute-Blanco L, Serrano I, Martínez Selles M, et al. Renal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure. Frontiers in Cardiovascular Medicine. 2022;9.
dc.identifier.issn2297-055X
dc.identifier.otherhttps://portalcientifico.sergas.gal/documentos/63418e6d29543f68c1401290*
dc.identifier.urihttp://hdl.handle.net/20.500.11940/20739
dc.description.abstractIntroduction: Galectin-3 (Gal-3) is an inflammatory marker associated with the development and progression of heart failure (HF). A close relationship between Gal-3 levels and renal function has been observed, but data on their interaction in patients with acute HF (AHF) are scarce. We aim to assess the prognostic relationship between renal function and Gal-3 during an AHF episode. Materials and Methods: This is an observational, prospective, multicenter registry of patients hospitalized for AHF. Patients were divided into two groups according to estimated glomerular filtration rate (eGFR): preserved renal function (eGFR ? 60 mL/min/1.73 m2) and renal dysfunction (eGFR <60 mL/min/1.73 m2). Cox regression analysis was performed to evaluate the association between Gal-3 and 12-month mortality. Results: We included 1,201 patients in whom Gal-3 values were assessed at admission. The median value of Gal-3 in our population was 23.2 ng/mL (17.3-32.1). Gal-3 showed a negative correlation with eGFR (rho = ?0.51; p < 0.001). Gal-3 concentrations were associated with higher mortality risk in the multivariate analysis after adjusting for eGFR and other prognostic variables [HR = 1.010 (95%-CI: 1.001-1.018); p = 0.038]. However, the prognostic value of Gal-3 was restricted to patients with renal dysfunction [HR = 1.010 (95%-CI: 1.001-1.019), p = 0.033] with optimal cutoff point of 31.5 ng/mL, with no prognostic value in the group with preserved renal function [HR = 0.990 (95%-CI: 0.964-1.017); p = 0.472]. Conclusions: Gal-3 is a marker of high mortality in patients with acute HF and renal dysfunction. Renal function influences the prognostic value of Gal-3 levels, which should be adjusted by eGFR for a correct interpretation.en
dc.description.sponsorshipThis work was supported by grants from Redes Tematicas de Investigacion Cooperativa en Salud del Instituto de Salud Carlos III (REDINSCOR), Madrid, Spain (Grant No. RD06-0003-0000) and Red de Investigacion Cardiovascular del Instituto de Salud Carlos III (RIC), Madrid, Spain (Grant No. RD12/0042/0002).en
dc.language.isoeng
dc.rightsAtribución 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.titleRenal Function Impact in the Prognostic Value of Galectin-3 in Acute Heart Failure*
dc.typeArticleen
dc.authorsophosCaravaca Perez, J. F. P.
dc.authorsophosGonzález-Juanatey, J. R.
dc.authorsophosNuche, J.
dc.authorsophosMatute-Blanco, L.
dc.authorsophosSerrano, I.
dc.authorsophosMartínez Selles, M.
dc.authorsophosVázquez García, R.
dc.authorsophosMartínez Dolz, L.
dc.authorsophosGómez-Bueno, M.
dc.authorsophosPascual Figal, D.
dc.authorsophosCrespo-Leiro, M. G.
dc.authorsophosGarcía-Osuna, A.
dc.authorsophosOrdoñez-Llanos, J.
dc.authorsophosCinca Cuscullola, J.
dc.authorsophosGuerra, J. M.
dc.authorsophosDelgado
dc.identifier.doi10.3389/fcvm.2022.861651
dc.identifier.sophos63418e6d29543f68c1401290
dc.journal.titleFrontiers in Cardiovascular Medicine*
dc.relation.projectIDRedes Tematicas de Investigacion Cooperativa en Salud del Instituto de Salud Carlos III (REDINSCOR), Madrid, Spain [RD06-0003-0000]; Red de Investigacion Cardiovascular del Instituto de Salud Carlos III (RIC), Madrid, Spain [RD12/0042/0002]
dc.relation.publisherversionhttps://www.frontiersin.org/articles/10.3389/fcvm.2022.861651/pdf;https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2022.861651/pdfes
dc.rights.accessRightsopenAccess
dc.subject.keywordAS Santiagoes
dc.subject.keywordCHUSes
dc.subject.keywordAS Coruñaes
dc.subject.keywordCHUACes
dc.subject.keywordINIBICes
dc.typefidesArtículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis)es
dc.typesophosArtículo Originales
dc.volume.number9


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional